IQ4I Research & Consultancy Published a New Report on "Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis"

Boston, MA, July 18, 2015 --(PR.com)-- “Nonalcoholic steatohepatitis (NASH) Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers.

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space.

Some of the key sections covered in the report are given below:

Epidemiology
In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.
Global & US prevalence rates